Search Our Scientific Publications & Authors

BMC Cancer 2021 Apr 7;21(1):360. Epub 2021 Apr 7.

Radiotherapy department, Centre de Lutte Contre le Cancer Jean PERRIN, 58 Rue Montalembert, 63011, Clermont-Ferrand, France.

Background: The rate of toxic deaths related to induction chemotherapy in the treatment of locally advanced head and neck cancers is unacceptable and calls into question this therapeutic strategy, which is however highly effective in terms of rate and speed of response. The purpose of the study was to investigate predictive factors of toxicity of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced head and neck cancers (LAHNC).

Methods: Between June 2009 and December 2017, 113 patients treated consecutively with TPF were included retrospectively. Read More

Anticancer Res 2021 Apr;41(4):2141-2145

Division of Gastroenterological Surgery, Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan.

Background/aim: We compared the outcome of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for unresectable locally advanced thoracic esophageal cancer (EC) with that of cisplatin (CDDP) and 5-fluorouracil (5-FU) as combination chemoradiotherapy (CF-RT) in clinical settings.

Patients And Methods: Seventy-three patients with unresectable locally advanced thoracic EC were included in this study. CF (n=38) consisted of intravenous CDDP at 70 mg/m (day 1) and 5-FU at 700 mg/m (days 1 to 4), repeated every four weeks for two cycles. Read More

Anticancer Res 2021 Apr;41(4):2045-2051

Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Japan;

Background/aim: To retrospectively evaluate the efficacy and safety of modified TPEx (docetaxel 60 mg/m on day 1, cisplatin 60 mg/m on day 1, and weekly cetuximab 250 mg/m with loading dose of 400 mg/m) followed by maintenance cetuximab as first-line treatment for inoperable recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Patients And Methods: We analyzed 22 Japanese patients receiving modified TPEx every 21 days for four cycles with or without prophylactic granulocyte colony-stimulating factor (G-CSF).

Results: The best overall response rate was 55% [95% confidence interval (CI)=35-73]. Read More

Pharmaceutics 2021 Mar 25;13(4). Epub 2021 Mar 25.

Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2, Canada.

About half of cancer patients (50%) receive radiotherapy (RT) for the treatment of local tumors. However, one of the main obstacles in RT is the close proximity of adjacent organs at risk, resulting in treatment doses being limited by significant tissue toxicity, hence preventing the necessary dose escalation that would guarantee local control. Effective local cancer therapy is needed to avoid progression of tumors and to decrease the development of systemic metastases which may further increase the possibility of resection. Read More

Pharmacol Res 2021 Mar 30:105585. Epub 2021 Mar 30.

University of Illinois at Chicago, College of Pharmacy, Department of Pharmaceutical Sciences, 833 South Wood Street, Chicago, IL, 60612, USA. Electronic address:

Cancer is the second leading cause of death worldwide, and the World Health Organization estimates that one in six deaths globally is due to cancer. Chemotherapy is one of the major modalities used to treat advanced cancers and their metastasis. However, the existence of acquired and intrinsic resistance to anti-cancer drugs often diminishes their therapeutic effect. Read More